Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism


Author index

Page Path
Jo Eun Kim  (Kim JE) 1 Article
Bone Metabolism
Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
Wonjin Kim, Yoonjung Chung, Se Hwa Kim, Sehee Park, Jae Hyun Bae, Gyuri Kim, Su Jin Lee, Jo Eun Kim, Byeong-Woo Park, Sung-Kil Lim, Yumie Rhee
Endocrinol Metab. 2015;30(1):58-64.   Published online March 27, 2015
  • 3,780 View
  • 34 Download
  • 14 Citations
AbstractAbstract PDFPubReader   

Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast cancer. As AIs lower estrogen levels, they increase bone turnover and lower bone mass. We analyzed changes in serum sclerostin levels in Korean women with breast cancer who were treated with an AI.


We included postmenopausal women with endocrine-responsive breast cancer (n=90; mean age, 57.7 years) treated with an AI, and compared them to healthy premenopausal women (n=36; mean age, 28.0 years). The subjects were randomly assigned to take either 5 mg alendronate with 0.5 µg calcitriol (n=46), or placebo (n=44) for 6 months.


Postmenopausal women with breast cancer had significantly higher sclerostin levels compared to those in premenopausal women (27.8±13.6 pmol/L vs. 23.1±4.8 pmol/L, P<0.05). Baseline sclerostin levels positively correlated with either lumbar spine or total hip bone mineral density only in postmenopausal women (r=0.218 and r=0.233; P<0.05, respectively). Serum sclerostin levels increased by 39.9%±10.2% 6 months after AI use in postmenopausal women; however, no difference was observed between the alendronate and placebo groups (39.9%±10.2% vs. 55.9%±9.13%, P>0.05).


Serum sclerostin levels increased with absolute deficiency of residual estrogens in postmenopausal women with endocrine-responsive breast cancer who underwent AI therapy with concurrent bone loss.


Citations to this article as recorded by  
  • Voluntary Wheel Running Partially Compensates for the Effects of Global Estrogen Receptor-α Knockout on Cortical Bone in Young Male Mice
    Rebecca K. Dirkes, Nathan C. Winn, Thomas J. Jurrissen, Dennis B. Lubahn, Victoria J. Vieira-Potter, Jaume Padilla, Pamela S. Hinton
    International Journal of Molecular Sciences.2021; 22(4): 1734.     CrossRef
  • Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease
    Manish Adhikari, Jesús Delgado-Calle
    Current Osteoporosis Reports.2021; 19(3): 247.     CrossRef
  • Gestational and lactational exposure to BPA or BPS has minimal effects on skeletal outcomes in adult female mice
    Rebecca K. Dirkes, Rebecca J. Welly, Jiude Mao, Jessica Kinkade, Victoria J. Vieira-Potter, Cheryl S. Rosenfeld, Pamela S. Bruzina
    Bone Reports.2021; 15: 101136.     CrossRef
  • Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model
    Enas A. Fouad-Elhady, Hadeer A. Aglan, Rasha E. Hassan, Hanaa H. Ahmed, Gilane M. Sabry
    Heliyon.2020; 6(2): e03341.     CrossRef
  • Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer
    Sung Hye Kong, Jung Hee Kim, Sang Wan Kim, Chan Soo Shin
    Journal of Bone and Mineral Metabolism.2020; 38(5): 730.     CrossRef
  • Global estrogen receptor-α knockout has differential effects on cortical and cancellous bone in aged male mice
    Rebecca K. Dirkes, Nathan C. Winn, Thomas J. Jurrissen, Dennis B. Lubahn, Victoria J. Vieira-Potter, Jaume Padilla, Pamela S. Hinton, Vance L. Trudeau
    FACETS.2020; 5(1): 328.     CrossRef
  • The Emerging Role of Osteocytes in Cancer in Bone
    Emily G Atkinson, Jesús Delgado‐Calle
    JBMR Plus.2019;[Epub]     CrossRef
  • Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results
    Katsuhiko Nakatsukasa, Hiroshi Koyama, Yoshimi Ouchi, Hisako Ono, Kouichi Sakaguchi, Takayuki Matsuda, Makoto Kato, Takashi Ishikawa, Kimito Yamada, Mana Yoshimura, Kei Koizumi, Teruhisa Sakurai, Hideo Shigematsu, Shunji Takahashi, Shinichiro Taira, Masat
    Breast Cancer.2019; 26(1): 106.     CrossRef
  • Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
    Kristina Bojanić, Ines Bilić Ćurčić, Lucija Kuna, Tomislav Kizivat, Robert Smolic, Nikola Raguž Lučić, Kristina Kralik, Vatroslav Šerić, Gordana Ivanac, Sandra Tucak-Zorić, Aleksandar Včev, Martina Smolić
    Journal of Clinical Medicine.2018; 7(9): 287.     CrossRef
  • Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
    Peyman Hadji, Matti S. Aapro, Jean-Jacques Body, Michael Gnant, Maria Luisa Brandi, Jean Yves Reginster, M. Carola Zillikens, Claus-C. Glüer, Tobie de Villiers, Rod Baber, G. David Roodman, Cyrus Cooper, Bente Langdahl, Santiago Palacios, John Kanis, Nass
    Journal of Bone Oncology.2017; 7: 1.     CrossRef
  • Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice
    Abul Kalam, Sushama Talegaonkar, Divya Vohora
    Molecular and Cellular Endocrinology.2017; 440: 34.     CrossRef
  • Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease
    Michelle M. McDonald, Jesus Delgado-Calle
    Current Osteoporosis Reports.2017; 15(6): 532.     CrossRef
  • Differential profile of letrozole and exemestane on bone turnover markers in vinylcyclohexene diepoxide treated ovotoxic female mice
    Abul Kalam, Sushama Talegaonkar, Divya Vohora
    Fundamental & Clinical Pharmacology.2016; 30(5): 429.     CrossRef
  • Osteoblasts Are the Centerpiece of the Metastatic Bone Microenvironment
    Hyo Min Jeong, Sun Wook Cho, Serk In Park
    Endocrinology and Metabolism.2016; 31(4): 485.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism